2 April 2020 in Neurological Research
Objectives: The ubiquitin/proteasome system is one of the main axes of the pathogenesis of Parkinson’s disease (PD). Small ubiquitin-related modifier (SUMO) proteins are involved in many biochemical events including regulation of transcriptional activity, modulation of signal transduction pathways, and response to cellular stress indicating a role for SUMO in the ubiquitin/proteasome system. Methods: In this study, our aim was to examine the prevalence of SUMO gene variants and their clinical associations in PD. Fifty-four consecutively recruited PD patients (34 male, 20 female) and 74 age-gender matched healthy controls (37 male, 37 female) were included. SUMO1, 2, 3 and 4 genes were screened by a next generation sequencing method using blood samples of participants. Single nucleotide polymorphisms (SNPs) with a significantly altered prevalence were determined by Bonferroni correction. Results: Two SNPs in the SUMO4 gene (rs237025 and rs237024) and two SNPs in the SUMO3 gene (rs180313 and rs235293) were found to have altered prevalence in PD. Although there was no association among these SNPs and clinical features of the patients, an increased family history of cancer was found in patients with SUMO3 gene variants. Discussion: Several SUMO SNPs were identified for the first time in PD patients suggesting that SUMO is involved in the pathophysiology of the disease. rs237025 has also been associated with diabetes mellitus indicating a pathogenic mechanism for SUMO that is shared with other degenerative disorders.
19 November 2020 in Turkish Journal of Hematology
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease resulting from the accumulation of genetic changes that affect the development of T-cells. The precise role of lymphoid enhancer-binding factor 1 (LEF1) in T-ALL has been controversial since both overexpression and inactivating LEF1 mutations have been reported to date. Here, we investigate the potential gene targets of LEF1 in the Jurkat human T-cell leukemia cell line. We used small interfering RNA (siRNA) technology to knock down LEF1 in Jurkat cells and then compared the gene expression levels in the LEF1 knockdown cells with nontargeting siRNA-transfected and non-transfected cells by employing microarray analysis. We identified DHRS2, a tumor suppressor gene, as the most significantly downregulated gene in LEF1 knockdown cells, and we further confirmed its downregulation by real-time quantitative polymerase chain reaction (qRT-PCR) in mRNA and at protein level by western blotting. Our results revealed that DHRS2 is positively regulated by LEF1 in Jurkat cells, which indicates the capability of LEF1 as a tumor suppressor and, together with previous reports, suggests that LEF1 exhibits a regulatory role in T-ALL via not only its oncogenic targets but also tumor suppressor genes.
1 December 2021 in Gene Reports
9 February 2023 in Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
Resumen: Objectivos: La leucemia mieloide aguda (AML, por sus siglas en inglés) es una enfermedad muy heterogénea. Aunque se puede clasificar a los pacientes en grupos de riesgo según sus mutaciones genéticas, el pronóstico dentro de cada categoría varía sustancialmente. Es perentorio identificar nuevos marcadores moleculares de la AML. Recientemente, se ha descrito la elevación del inhibidor de la serina peptidasa Kazal tipo 2 (SPINK2) en la AML, habiendo sido relacionada con peores resultados clínicos en metaanálisis, así como en un número limitado de pacientes con AML. Métodos: Analizamos la expresión de SPINK2 en 62 pacientes (45 adultos y 17 niños) con AML y en 11 líneas celulares mediante PCR cuantitativa (qRT-PCR). Los niveles de la proteína SPINK2 se determinaron en líneas celulares mediante ELISA. Resultados: Observamos un aumento de expresión del ARNm de SPINK2 y de los niveles de la proteína en las líneas celulares de AML (HL60 y NB4), frente a otras líneas celulares (K562, Jurkat y NALM6, MCF7, HeLa, HUVEC, hFOB, 293T, U87). Los pacientes con AML mostraron una expresión elevada de ARNm de SPINK2 frente a los controles (p=0,004) y esta fue significativamente menor en los pacientes t(8;21) positivos, frente a los pacientes negativos (p=0,0006). Conclusions: Estos resultados sugieren que el gen SPINK2 tiene un papel relevante en el desarrollo de la AML. Son necesarios más estudios para evaluar la expresión de SPINK2 en los pacientes con AML con la mutación t(8.21) e investigar su valor pronóstico en varios subgrupos de pacientes con AML.
12 August 2026 in Experimed
Objective: The ubiquitin system plays a central role in regulating intracellular protein homeostasis and cellular signaling. E3 ubiquitin ligases, in particular, are key modulators of protein degradation and have been implicated in cancer progression, including breast cancer. DHRS2, a gene known to suppress MDM2 activity through its ubiquitin-binding domain, has recently emerged as a potential regulator in tumor biology. This study investigated how DHRS2 expression influences selected E3 ubiquitin ligase genes in breast epithelial cells.Materials and Methods: MCF-7 and MCF-10A cell lines were used. DHRS2 was either overexpressed using a vector-based system, or silenced via siRNA. After transfection, quantitative reverse transcription polymerase chain reaction (qRT–PCR) was performed to evaluate changes in the expression levels of BRCA1, BARD1, and STUB1.Results: In MCF-7 cells, DHRS2 overexpression induced a fourfold increase in BRCA1 expression, whereas STUB1 and BARD1 were downregulated (0.56-fold). In MCF-10A cells with naturally low DHRS2, STUB1 expression increased 1.5-fold after DHRS2 knockdown, and BARD1 expression correlated positively with DHRS2 levels.Conclusion: This study highlights a potential regulatory link between DHRS2 and key E3 ubiquitin ligases-BRCA1, BARD1, and STUB1. Differential patterns across cell types indicate DHRS2 as a context-dependent modulator of ubiquitin-mediated pathways, supporting its relevance in biomarker discovery and therapeutic targeting in breast cancer.
10 August 2026 in Molecular Biology Reports